Arvinas Stock Earnings Reports

Arvinas reported progress across a broad PROTAC pipeline and reiterated financial discipline. Clinically, ARV-102 (brain-penetrant LRRK2 degrader) showed strong PK/PD, brain penetration, up to ~90% PBMC LRRK2 reduction and >50% CSF reduction in healthy volunteers, and pathway biomarker changes after 14 days suggesting rapid engagement; Parkinson's and PSP development is planned with further data updates in 2026. ARV-393 (BCL6 degrader) is in a Phase I dose-escalation: early cohorts (below predicted efficacious exposures) already show responses in B- and T-cell lymphomas with evidence of robust BCL6 degradation and tolerability; combination trials (e.g., with glofitamab) are planned. ARV-806 (KRAS G12D degrader) presented strong preclinical potency and durability, is enrolling a Phase I trial, and is differentiated versus existing inhibitors/degraders. Additional preclinical programs include ARV-027 (polyQ-AR for SBMA) and ARV-6723 (HPK1 degrader for IO) with planned first-in-human studies in 2026 and more preclinical data at ASH and SITC. Corporate/financial highlights: cash, cash equivalents and marketable securities of $787.6M at 9/30/25, runway into second half of 2028, ongoing cost-reduction measures, target non-GAAP quarterly run rate below $75M and non-GAAP FY2026 expenses < $300M, and a Board-authorized $100M share repurchase program (2.56M shares repurchased to date at $7.91 average). Business-development/near-term commercial: vepdegestrant (vepdeg) NDA under FDA review with PDUFA date June 5, 2026; Pfizer/Arvinas are selecting a commercialization partner to be in place ahead of PDUFA. Key upcoming catalysts: multiple clinical readouts and starts through 2026 (LRRK2 MAD/PD data, PSP initiation, ARV-393 and ARV-806 clinical updates), ASH and SITC preclinical presentations in coming weeks/months.